{"id":"W3082374255","doi":"10.1111/apt.16060","title":"Long‐term safety of vedolizumab for inflammatory bowel disease","year":2020,"lang":"en","type":"article","venue":"Alimentary Pharmacology & Therapeutics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":191,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Bible College","funders":"Takeda Pharmaceutical Company","keywords":"Vedolizumab; Medicine; Ulcerative colitis; Internal medicine; Discontinuation; Gastroenterology; Adverse effect; Inflammatory bowel disease; Crohn's disease; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011474,0.0002664924,0.0001911811,0.00003403204,0.0001068753,0.000007956352,0.0003753542,0.0001209321,0.0001907987],"category_scores_gemma":[0.000001050918,0.0002861517,0.0002220516,0.00004724333,0.0002322208,0.00001058674,0.0001586198,0.0001067782,0.00001670515],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003027708,"about_ca_system_score_gemma":0.0002284277,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":7.797419e-7,"about_ca_topic_score_gemma":0.000002202005,"domain_scores_codex":[0.9985313,0.0001390857,0.0004080202,0.000415992,0.0001416493,0.0003639804],"domain_scores_gemma":[0.9990855,0.00002959736,0.0001755759,0.0002809723,0.0001029533,0.0003253863],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01692684,0.0003539804,0.1353184,0.0003471454,0.006243594,0.0001305352,0.0002743341,0.0004577205,0.8364483,0.00007479232,0.002507483,0.0009168964],"study_design_scores_gemma":[0.01267367,0.001058338,0.4054793,0.00002857796,0.009376819,0.000009236667,0.0001016406,0.001346926,0.5344274,0.00009519786,0.03438146,0.001021396],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994112,0.001381983,0.0006748988,0.001860586,0.0004850811,0.0009851112,0.0003960017,0.00003550532,0.00006878778],"genre_scores_gemma":[0.9724166,0.0005597408,0.0002046354,0.02538342,0.0006400314,0.0001113599,0.0005509867,0.00006281915,0.00007036962],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3020209,"threshold_uncertainty_score":0.9999591,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01966195509693977,"score_gpt":0.292556701332228,"score_spread":0.2728947462352882,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}